The APOE Knockout A-549 Polyclonal Cells product comprises a population of CRISPR/Cas9-edited A-549 human lung adenocarcinoma cells with targeted disruption of the APOE gene. This polyclonal knockout pool is generated without single-cell cloning, providing a heterogeneous loss-of-function model that reflects the inherent genetic diversity of a knockout population. The APOE gene encodes apolipoprotein E, a critical regulator of lipid transport and cholesterol homeostasis with broad implications in Alzheimer??s disease, atherosclerosis, and lipoprotein metabolism. This product provides researchers with a robust cellular tool for investigating APOE-dependent pathways in a lung epithelial background.
A-549 is a widely used human lung adenocarcinoma cell line originally derived from alveolar basal epithelial cells. As a type II pneumocyte-like line, A-549 cells retain features of alveolar epithelium and are commonly employed in studies of lung cancer biology, drug metabolism, and epithelial barrier function. The A-549 background offers a unique platform to examine APOE function in a non-hepatic, non-astrocytic context, especially given the emerging role of pulmonary lipid metabolism in inflammation and cancer progression. These cells express multiple lipoprotein receptors and respond to inflammatory cytokines, making them suitable for dissecting APOE-mediated lipid handling and inflammatory crosstalk.
Apolipoprotein E (APOE) serves as a ligand for receptor-mediated endocytosis of lipoprotein particles, facilitating cholesterol efflux and lipid redistribution among cells. APOE interacts with membrane heparan sulfate proteoglycans (HSPG) and lipid transporters such as ABCA1, and its activity is regulated by transcription factors including PPAR?? and LXR. Inflammatory stimuli like TNF-?? and IL-1?? modulate APOE expression, linking it to neuroinflammation and peripheral lipid responses. Downstream of APOE, key receptors LDLR, LRP1, and VLDLR mediate the cellular uptake of APOE-containing lipoproteins, while APOE also participates in A?? clearance, a process relevant to Alzheimer??s pathology. This signaling network, involving APOE, LDLR, LRP1, ABCA1, and ABCG1, positions APOE at the intersection of lipid metabolism and inflammatory signaling.
In the A-549 cell context, CRISPR/Cas9-mediated APOE disruption abrogates APOE-dependent cholesterol efflux and lipid homeostasis, potentially altering membrane composition and cellular responses to metabolic stress. Given that A-549 cells are of tumor origin, this knockout model can unravel how APOE loss influences cancer cell lipid utilization, proliferation, and sensitivity to chemotherapeutic agents. Furthermore, because APOE modulates inflammatory pathways, these polyclonal knockout cells may exhibit altered secretion of cytokines and lipid mediators, offering insights into the lung??s microenvironment in diseases like chronic obstructive pulmonary disease and lung adenocarcinoma progression.
This APOE knockout polyclonal population is suitable for a wide range of experimental applications, including cholesterol efflux and lipid uptake assays to probe metabolic flux, Western blotting and RT-qPCR for validating downstream target expression (e.g., LDLR, LRP1), and immunofluorescence or flow cytometry for assessing receptor distribution. Functional studies may utilize cell viability and migration assays to evaluate the role of APOE in tumor cell behavior under lipid-depleted or inflammatory conditions. Drug screening campaigns targeting APOE-related disorders such as Alzheimer??s disease and atherosclerosis can also be implemented. For detailed technical specifications or custom inquiries, please contact Ascent Research.
